

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 417/12, 277/34 A61K 31/425	A1	(11) International Publication Number: WO 92/07850 (43) International Publication Date: 14 May 1992 (14.05.92)
(21) International Application Number: PCT/GB91/01833 (22) International Filing Date: 18 October 1991 (18.10.91) (30) Priority data: 9023584.7 30 October 1990 (30.10.90) GB (71) Applicant (for all designated States except US): BEECHAM GROUP PLC [GB/GB]; SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : CANTELLO, Barrie, Christian, Charles [GB/GB]; HAIGH, David [GB/GB]; HINDLEY, Richard, Mark [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).		(74) Agent: RUTTER, Keith; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i>

(54) Title: NOVEL COMPOUNDS**(57) Abstract**

A compound of formula (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A^1 represents an alkyl group, a substituted or unsubstituted aryl group, an aralkyl group wherein the alkylene or the aryl moiety may be substituted or unsubstituted or a substituted or unsubstituted aromatic heterocyclic group; A^2 represents a benzene ring having in total up to three optional substituents; R^1 represents a hydrogen atom, an alkyl group, an aralkyl group wherein the alkyl or the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; or A^1 together with R^1 represents substituted or unsubstituted C_{3-4} polymethylene group, optional substituents for the polymethylene group being selected from alkyl or aryl or adjacent substituents together with the methylene carbon atoms to which they are attached form a substituted or unsubstituted phenylene group; R^2 and R^3 each represent hydrogen, or R^2 and R^3 together represent a bond; X represents O or S; and n represents an integer in the range of from 2 to 6; a process for preparing such a compound, a composition comprising such a compound and the use of such a compound and composition in medicine.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	CA	Gahon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

European Patent Applications, Publication Numbers 0008203, 0139421, 0155845, 0177353, 0193256, 0207581 and 0208420 relate to thiazolidinedione derivatives which are disclosed as having hypoglycaemic and hypolipidaemic activity. Chem. Pharm. Bull 30 (10) 3580-3600 also relates to certain thiazolidinedione derivatives having hypoglycaemic and hypolipidaemic activities.

20 These compounds are also indicated to be of potential use for the treatment and/or prophylaxis of other diseases including hyperlipidaemia, hypertension, cardiovascular disease and certain eating disorders.

$$A^1 - CO - \overset{\overset{R^1}{|}}{N} - (CH_2)_n - X - \text{---} \bigcirc A^2 \text{---} \overset{\overset{R^2}{|}}{CH} - \overset{\overset{R^3}{|}}{C} \begin{array}{l} \diagup O \\ \diagdown \end{array} \begin{array}{l} \diagdown NH \\ \diagup O \end{array} \quad (I)$$

or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A¹ represents an alkyl group, a substituted or unsubstituted aryl group, an aralkyl group wherein the alkylene or the aryl moiety may be substituted or unsubstituted or a substituted or unsubstituted aromatic heterocyclyl group;

- 2 -

A² represents a benzene ring having in total up to three optional substituents;

R¹ represents a hydrogen atom, an alkyl group, an aralkyl group wherein the alkyl or the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

or A¹ together with R¹ represents substituted or unsubstituted C₃₋₄ polymethylene group, optional substituents for the polymethylene group being selected from alkyl or aryl or adjacent substituents together with the methylene carbon atoms to which they are attached form a substituted or unsubstituted phenylene group;

R² and R³ each represent hydrogen, or R² and R³ together represent a bond;

X represents O or S; and

n represents an integer in the range of from 2 to 6.

When A¹ represents an aryl group, the aryl group is suitably an unsubstituted aryl group, for example a phenyl group.

When A¹ represents an aralkyl group, the aralkyl group is suitably a group of formula aryl(CH₂)_m, wherein m is 1, 2, 3 or 4, preferably 1 or 2, for example a benzyl group.

When A¹ represents an aryl group or an aralkyl group, favoured substituents for the aryl group or the aryl moiety of the aralkyl group are halogen and alkoxy, for example chlorine and methoxy.

Particular examples of A¹ include phenyl, benzyl and 2-phenylethyl.

Favourably, A¹ together with R¹ represents substituted or unsubstituted C₃₋₄ polymethylene group, optional substituents for the polymethylene group being selected from alkyl or aryl or adjacent substituents together with the methylene carbon atoms to which they are attached form a substituted or unsubstituted phenylene group.

Favoured substituted or unsubstituted C₃₋₄-polymethylene groups include substituted or unsubstituted propylene groups.

Favoured optional substituents for the C₃₋₄-polymethylene group, include

- 3 -

C₁₋₆-alkyl and phenyl groups or adjacent substituents together with the methylene carbon atoms to which they are attached form an optionally substituted phenylene group.

- 5 Preferred optional substituents for the C₃₋₄ polymethylene group are adjacent substituents which together with the methylene carbon atoms to which they are attached form an optionally substituted phenylene group.

- 10 In a particularly favoured aspect, the moiety A¹-CO-NR¹ represents a 2,3-dihydro-1H-isoindol-1-on-2-yl group or a 3,4-dihydro-2H-isoquinolin-on-2-yl group wherein the phenylene moiety may be substituted or, most preferably, unsubstituted.

- 15 Optional substituents for the phenylene group are selected from: halogen, alkyl, phenyl, alkoxy, haloalkyl, hydroxyalkyl, hydroxy, amino, nitro, cyano, carboxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy and alkylcarbonyl groups.

- 20 Preferably, the phenylene group is unsubstituted.

Suitable substituted or unsubstituted aromatic heterocyclyl groups include substituted or unsubstituted, single or fused ring aromatic heterocyclyl groups comprising up to 4 heteroatoms in each ring selected from oxygen, sulphur or nitrogen.

- 25 Favoured aromatic heterocyclyl groups include substituted or unsubstituted single ring aromatic heterocyclyl groups having 4 to 7 ring atoms, preferably 5 or 6 ring atoms.


- 30 In particular, the aromatic heterocyclyl group comprises 1, 2 or 3 heteroatoms, especially 1 or 2, selected from oxygen, sulphur or nitrogen.

A favoured aromatic heterocyclyl group is a pyridyl group, in particular a 2-pyridyl group.

- 35 Suitable substituents for the moiety A² include halogen, substituted or unsubstituted alkyl or alkoxy.

- 4 -

Favourably, A² represents a moiety of formula (a):



wherein R⁴ and R⁵ each independently represent hydrogen, halogen, substituted or unsubstituted alkyl or alkoxy.

10 Suitably, R⁴ and R⁵ each independently represent hydrogen, halogen, unsubstituted alkyl or alkoxy.

Preferably, R⁴ and R⁵ each represent hydrogen.

15 Suitably, R¹ represents hydrogen, alkyl, acyl, especially acetyl, or benzyl.

Favourably, R¹ represents hydrogen and methyl.

Preferably, R¹ represents a methyl group.

20

Suitably, R² together with R³ represents a bond.

Preferably, R² and R³ each represent hydrogen.

25 In one aspect, X represents sulphur. Preferably, X represents oxygen.
Suitably, n represents an integer 2, 3 or 4, notably 2 or 3 and especially 2.

As indicated above a compound of formula (I) may exist in one of several tautomeric forms, all of which are encompassed by the present invention.

30 It will be appreciated that the present invention encompasses all of the isomeric forms of the compounds of formula (I) and the pharmaceutically acceptable salts thereof, including any stereoisomeric forms thereof, whether as individual isomers or as mixtures of isomers.

35 When used herein the term 'aryl' includes phenyl and naphthyl, preferably phenyl, optionally substituted with up to five, preferably up to three, groups selected from halogen, alkyl, phenyl, alkoxy, haloalkyl, hydroxyalkyl, hydroxy, amino, nitro, cyano, carboxy, alkoxycarbonyl,

- 5 -

alkoxycarbonylalkyl, alkylcarbonyloxy, or alkylcarbonyl groups.

Suitable substituents for any heterocyclyl group include up to 4 substituents selected from the group consisting of: alkyl, alkoxy, aryl and
5 halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, preferably a benzene ring, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted.

10

When used herein the term 'halogen' refers to fluorine, chlorine, bromine and iodine; preferably chlorine.

15

When used herein the terms 'alkyl' (or 'alk' as used for example in 'alkoxy' or 'alkylene') relate to alkyl groups having straight or branched carbon chains, containing up to 12 carbon atoms.

20

Suitable alkyl groups are C₁₋₁₂ alkyl groups, especially C₁₋₆ alkyl groups e.g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl or tert-butyl groups.

Suitable pharmaceutically acceptable salts include salts of the thiazolidinedione moiety, and, where appropriate, salts of carboxy groups.

25

Suitable pharmaceutically acceptable salts of the thiazolidinedione moiety include metal salts especially alkali metal salts such as the lithium, sodium and potassium salts.

30

Suitable pharmaceutically acceptable salts of carboxy groups include metal salts, such as for example aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or
35 tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-b-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine,


- 6 -

collidine or quinoline.

Suitable pharmaceutically acceptable solvates include hydrates.

- 5 In a further aspect the present invention also provides a process for the preparation of a compound of formula (I), or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, which process comprises reacting a compound of formula (II):

10




15

(II)

wherein R^2 , R^3 and A^2 are as defined in relation to formula (I), and R^a is a moiety convertible to a moiety of formula (b):

20



(b)

- 25 wherein A^1 , R^1 , X and n are as defined in relation to formula (I), with an appropriate reagent capable of converting R^a to the said moiety (b) and thereafter, if required, carrying out one or more of the following optional steps:

- 30 (i) converting a compound of formula (I) into a further compound of formula (I);

- (ii) preparing a pharmaceutically acceptable salt of the compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.

- 35 For compounds of formula (I), other than those wherein A^1 together with R^1 represent a substituted or unsubstituted C_{3-4} polymethylene group, R^a suitably represents $R^{1a}HN-(CH_2)_n-X-$ wherein X and n are as defined in relation to formula (I) and R^{1a} represents hydrogen, alkyl or aralkyl,

- 7 -

wherein the alkyl or aryl moiety may be substituted or unsubstituted, or substituted or unsubstituted aryl.

5 Suitably, when R^a is $R^{1a}HN-(CH_2)_n-X$, an appropriate reagent capable of converting R^a into a moiety (b) is a compound of formula (III):



(III)

10 wherein A^3 is alkyl, substituted or unsubstituted aryl, aralkyl substituted or unsubstituted in the aryl or alkyl moiety or a substituted or unsubstituted heterocyclyl group and L^1 represents a leaving group.

A suitable leaving group L^1 includes a halogen atom, preferably a chlorine or bromine atom, or an alkoxy group.

15

The reaction between the compound of formula (II) and the appropriate reagent may be carried out under conditions suitable to the particular compound of formula (II) and the reagent chosen; thus for example the abovementioned reaction between a compound of formula (II) wherein R^a represents $R^{1a}HN-(CH_2)_n-X$ and the compound of formula (III), may be carried out in any suitable solvent, for example tetrahydrofuran, at a temperature in the range of between 0 and 100°C, suitably at 80°C, and preferably in the presence of an organic base, such as triethylamine and/or 4-dimethylaminopyridine and optionally in the presence of

20

25 trimethylsilylchloride.

Alternatively, R^a represents $-XH$, wherein X is as defined in relation to formula (I), or R^a represents a leaving group or atom, such as a halogen atom, and especially a fluorine atom.


30

Preferably, R^a represents $-XH$, wherein X is defined in relation formula (I).

When R^a represents $-XH$, a particularly appropriate reagent is a compound of formula (IV);

35

- 8 -



- 5 wherein A^1 , R^1 , X and n are as defined in relation to formula (I) and L^2 represents a leaving group such as a mesyl or tosyl group.

The reaction between the compounds of formulae (II) and (IV) may be carried out in any suitable aprotic solvent, for example
 10 dimethylformamide, at any temperature providing a suitable rate of formation of the required product, conveniently at an elevated temperature, for example in the range of from 60°C to 100°C; the reaction is generally carried out in the presence of a base, such as sodium hydride and in an inert atmosphere.

15 When R^a is a leaving group or atom such as a halogen atom, and especially a fluorine atom, a particularly suitable reagent is a compound of formula (VII) as defined hereinafter. Reaction conditions for the reaction between the compounds of formulae (II) wherein R^a is a leaving
 20 group or atom, such as halogen and especially fluorine, is analogous to those described hereinafter in relation to the compounds of formulae (V) and (VIIA).

A compound of formula (II) may be prepared by reacting a compound of
 25 formula (V):



(V)

35 wherein A^2 is as defined in relation to formula (I), and R^b represents R^a or a protected form thereof with 2,4-thiazolidinedione or a protected form thereof; and thereafter, if required, converting a compound of formula (II)

- 9 -

wherein R^2 and R^3 together represent a bond to give a compound of formula (II) wherein R^2 and R^3 each represent hydrogen and/or removing any protecting group and/or converting one group R^a into another group R^a .

5

The reaction between the compound of formula (V) and 2,4-thiazolidinedione will of course be carried out under conditions suitable to the nature of the compound of formula (V), in general the reaction being carried out in a solvent such as toluene, suitably at an elevated temperature such as the reflux temperature of the solvent and preferably in the presence of a suitable catalyst such as piperidinium acetate or benzoate. Favourably, in the reaction between the compound of formula (V) and 2,4-thiazolidinedione, the water produced in the reaction is removed from the reaction mixture, for example by means of a Dean and Stark apparatus.

15


For compounds of formula (II) wherein R^a is HX -, R^b suitably represents a protected form of R^a , for example a group R^cX - where R^c is a benzyl group.

20

The interconversion of one group R^a into another may be effected by any suitable procedure: for example a compound of formula (II) wherein R^a is $R^{1a}HN-(CH_2)_n-X$ may be prepared from the corresponding compound of formula (II) wherein R^a is $-XH$; thus the appropriate conversion may be carried out by coupling a compound of formula (IIA):

25

30



wherein R^2 , R^3 , A^2 and X are as defined in relation to formula (I) and R^d is hydrogen or a nitrogen protecting group, with a compound of formula (VI):

35



- 10 -

wherein R^{1a} and n are as defined above and R^e is hydrogen or a nitrogen protecting group, in the presence of a suitable coupling agent; and thereafter, if required, carrying out one or more of the following optional steps:

5

(i) reducing a compound of formula (II) wherein R^2 and R^3 together represent a bond, to a compound of formula (II) wherein R^2 and R^3 each represent hydrogen;

10 (ii) removing any nitrogen protecting group.

A suitable coupling agent for the coupling reaction between the compound of formula (IIA) and (VI) is provided by diethylazodicarboxylate and triphenylphosphine. The coupling reaction may be carried out in any
15 suitable solvent at a low to medium temperature, for example in tetrahydrofuran at a temperature in the range of between 0 and 60°C.

A compound of formula (IV) may be prepared by suitable conversion of a compound formula (VII):

20



25 wherein A^1 , R^1 , X and n are as defined in relating to formula (I); for example when L^2 in (IV) represents mesyl or tosyl group the suitable conversion may be effected by mesylation or tosylation, as appropriate, in an inert solvent such as dichloromethane at any temperature providing a suitable rate of formation of the required product, conveniently at room
30 temperature or lower, for example at 0°C, and preferably in the presence of a base such as triethylamine.

A compound of formula (VII) wherein A^1 represents alkyl, substituted or unsubstituted aryl, an aralkyl group substituted or unsubstituted in the
35 alkyl or aryl moiety or A^1 represents -Y-B wherein Y is a bond or an alkylene group and B represents a substituted or unsubstituted aromatic heterocyclyl group and R^1 represents R^{1a} , as defined above, may be prepared by reacting a compound of the hereinbefore defined formula (III)

- 11 -

with a compound of formula (VIII):




wherein R^{1a} and n are as defined above.

- 10 The reaction between the compounds of formulae (III) and (VIII) may be carried out using conventional peptidation conditions: the reaction is conveniently effected in a biphasic solvent system such as water/chloroform or in water only in the presence of a base such as sodium carbonate, or sodium hydroxide at a temperature providing a convenient
- 15 rate of formation of the required product, suitably at room temperature or lower, for example at 0°C . Alternatively, where convenient, the compound of formula (VIII) may be used as solvent, the reaction being carried out at an elevated temperature, suitably at the reflux temperature of the solvent: This latter variation of the reaction is particularly suitable when the
- 20 compound of formula (VIII) is an ethanolamine.

A compound of formula (VII) wherein A^1 together with R^1 represents a substituted or unsubstituted C_{3-4} -polymethylene group, as defined in relation to formula (I), may be prepared by reacting a compound of

25 formula (IX):



wherein Z represents the substituted or unsubstituted C_{3-4} -polymethylene group as defined in relation to formula (I), with a

35 compound of formula (X):




- 12 -

wherein n and X are as defined in relation to formula (I), L³ represents a leaving group, preferably a bromine atom, and R^f represents hydrogen or a protecting group.

- 5 The reaction between compounds of formulae (IX) and (X) may be carried out in any suitable aprotic solvent, such as dimethylformamide, at any temperature providing a suitable rate of formation of the required product, suitably at a temperature in the range of from 0° to 100°C, for example 80°C and preferably in the presence of a base such as potassium carbonate or sodium hydride.

Preferably, X represents O.

- 15 A compound of formula (I), or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may also be prepared by reacting a compound of formula (XI):



- 25 wherein R¹, A¹, A², X and n are as defined in relation to formula (I) with 2,4-thiazolidinedione; and thereafter if required carrying out one or more of the following optional steps:

30 (i) converting a compound of formula (I) into a further compound of formula (I);

(ii) preparing a pharmaceutically acceptable salt of a compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.

- 35 The reaction between the compound of formula (XI) and 2,4-thiazolidinedione will of course be carried out under conditions suitable to the nature of the compound of formula (XI), in general the reaction being carried out in a solvent such as toluene, suitably at an

- 13 -

elevated temperature such as the reflux temperature of the solvent and preferably in the presence of a suitable catalyst such as piperidinium acetate or benzoate. Favourably, in the reaction between the compound of formula (XI) and 2,4-thiazolidinedione, the water produced in the reaction is removed from the reaction mixture, for example by means of a Dean and Stark apparatus.

A compound of formula (XI) may be prepared from a compound of formula (V), or a protected form thereof, wherein R^b represents R^a , by reaction, with an appropriate reagent capable of converting R^a to the above defined moiety (b).

Suitable values for R^a include those described above in relation to the compound of formula (II). Appropriate reagents are also described above in relation to formula (II).

Suitable reaction conditions for the reaction of the compound of formula (V) and the appropriate reagent include those described above in relation to the preparation of compound (II) with the said appropriate reagent.

Suitable protected forms of compounds of formula (V) include those wherein the aldehyde group is protected. Suitable protecting groups are those used conventionally in the art. It has been found convenient to protect the aldehyde group by reducing it to a hydroxymethyl group, deprotection is conveniently effected by oxidation back to the aldehyde. Suitable reducing agents are conventional agents such as complex metal hydride reducing agents such as lithium aluminium hydride or as appropriate, the use of a zinc powder/acetic acid reducing agent. Suitable oxidising agents are conventional oxidising agents such as $Mn^{IV}O_2$.

In one preferred aspect for preparing compounds of formula (XI), R^b in compound (V) represents a leaving group or atom, especially a fluorine atom: When R^b represents a leaving group or atom, especially a fluorine atom, a particularly appropriate reagent is a compound of the above defined formula (VII):

The reaction between the compounds of formulae (V) and (VII) may be carried out under any suitable conditions, for example in a solvent such as

- 14 -

dimethylformamide or dimethylsulphoxide at an elevated temperature for example in the range of from 60 to 150°C, suitably in the presence of a base such as sodium hydride, sodium hydroxide or potassium carbonate and preferably in an inert atmosphere such as nitrogen.

5

In a further aspect, when R^b in the compound of formula (V) represents a moiety of the above defined formula $R^{1a}HN(CH_2)_nX-$, then a particularly appropriate reagent is a compound of the abovedefined formula (III).

- 10 The reaction between the compound of formula (V), wherein R^a is a moiety $R^{1a}HN(CH_2)_2-X-$, and the reagent of formula (III) is generally carried out under conditions analogous to those disclosed above in relation to the reaction between the compounds of formulae (II) and (III).

- 15 Preferably in the abovementioned reaction, the aldehyde group of the compound of formula (V) is in a protected form: a convenient protected form is provided by reducing the aldehyde to a hydroxymethyl group, as described herein, and thereafter oxidising the hydroxymethyl group to the aldehyde as described herein.

20

Compounds of formula (V) wherein R^b is a protected form of R^a may be prepared from the corresponding compound of formula (V) wherein R^b is R^a .

- 25 The compounds of formula (V) wherein R^b is hydroxyl or fluorine are known compounds or compounds prepared by methods analogous to those used to prepare known compounds, for example 4-fluorobenzaldehyde and 4-hydroxybenzaldehyde are known commercially available compounds and the compounds of formula (V) wherein R^b is SH are prepared
30 according to methods disclosed in Beilstein 8.I.533.

The abovementioned conversion of a compound of formula (I) into a further compound of formula (I) includes the following conversions:

- 35 (a) reducing a compound of formula (I) wherein R^2 and R^3 together represent a bond, to a compound of formula (I) wherein R^2 and R^3 each represent hydrogen; and

- 15 -

(b) converting one group R^1 into another group R^1 .

5 The conversion of a compound of formula (I) to a further compound of formula (I) may be carried out by using any appropriate conventional procedure.

A suitable reduction method for the abovementioned conversion (a) includes catalytic reduction or the use of a metal/solvent reducing system.

10 Suitable catalysts for use in the catalytic reduction are palladium on carbon catalysts, preferably a 10% palladium on charcoal catalyst; the reduction being carried out in a solvent, for example dioxan, suitably at ambient temperature.

15 Suitable metal/solvent reducing systems include magnesium in methanol.

The abovementioned reduction of a compound of formula (II) wherein R^2 and R^3 together represent a bond to a compound of formula (II) wherein R^2 and R^3 each represent hydrogen, may be carried out under analogous
20 conditions to those referred to above in conversion (a) of the compound of formula (I).

In the abovementioned conversion (b), suitable conversions of one group R^1 into another group R^1 includes converting a group R^1 which
25 represents hydrogen into a group R^1 which represents an alkyl group.

The conversion of a compound of formula (I) wherein R^1 represents hydrogen into a compound of formula (I) wherein R^1 represents alkyl may be carried out using any appropriate conventional alkylation procedure,
30 such as by treating an appropriately protected compound of formula (I) with an alkyl halide, for example an alkyl iodide.

It will be appreciated that in the abovementioned conversions (a) and (b), any reactive group in the compound of formula (I) would be protected,
35 according to conventional chemical practice, where necessary.

The compounds of formula (III), (VIII), (VIIIA) and (X) are either known compounds or are prepared using methods analogous to those used to

- 16 -

prepare known compounds for example methods disclosed in Advanced Organic Chemistry, J. March, McGraw Hill.

5 A compound of formula (VI), wherein R^e is a nitrogen protecting group, may be prepared by suitably protecting the nitrogen atom of a compound of the abovedefined formula (VIII).

10 Suitable protecting groups in any of the abovementioned reactions are those used conventionally in the art. Thus, for example, a suitable nitrogen protecting group is a benzyl group or a benzyloxycarbonyl group and a suitable hydroxyl protecting group is a benzyl group.

15 Suitable protecting groups in any of the abovementioned reactions are those used conventionally in the art. Thus, for example, a suitable nitrogen protecting group is a benzyl group or a benzyloxycarbonyl group or, especially for the thiazolidinedione nitrogen, a trimethylsilyl group or an allyl group and a suitable hydroxyl protecting group is a benzyl group.

20 The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected. Thus for example an N- benzyl group may be prepared by treatment of the appropriate amine with a benzyl halide, such as benzyl bromide, and thereafter when required the benzyl group may be conveniently removed using catalytic hydrogenation.

25 Where appropriate the isomeric forms of the compounds of formula (I) and the pharmaceutically acceptable salts thereof may be prepared as individual isomers using conventional chemical procedures.

30 Pharmaceutically acceptable salts and/or solvates of the compounds of formula (I) may be prepared according to conventional procedures.

35 As mentioned above the compounds of the invention are indicated as having useful therapeutic properties:

The present invention accordingly provides a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use as an active

- 17 -

therapeutic substance.

Thus the present invention provides a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof
5 and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of hyperglycaemia.

In a further aspect the present invention also provides a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically
10 acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment and/or prophylaxis of hyperlipidaemia.

As indicated hereinbefore the present invention also provides a compound of formula (I) or a tautomeric form thereof and/or a pharmaceutically
15 acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof for use in the treatment of hypertension, cardiovascular disease and certain eating disorders.

A compound of formula (I), or a tautomeric form thereof and/or a
20 pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.

25 Accordingly, the present invention also provides a pharmaceutical composition comprising a compound of the general formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.

30 As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.

35 The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.

- 18 -

Usually the pharmaceutical compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.

5

Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used.

10 In accordance with conventional pharmaceutical practice the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant.

15 Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, sodium lauryl sulphate or sucrose.

20 Most suitably the composition will be formulated in unit dose form. Such unit dose will normally contain an amount of the active ingredient in the range of from 0.1 to 1000 mg, more usually 0.1 to 500 mg, and more especially 0.1 to 250 mg.

25 The present invention further provides a method for the treatment and/or prophylaxis of hyperglycaemia in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of the general formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a hyperglycaemic human or non-human mammal in need thereof.

30

35 The present invention further provides a method for the treatment of hyperlipidaemia in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, to a hyperlipidaemic human or non-human mammal in need thereof.

Conveniently, the active ingredient may be administered as a

- 19 -

pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.

5 In the treatment and/or prophylaxis of hyperglycaemic humans, and/or the treatment and/or prophylaxis of hyperlipidaemic human, the compound of the general formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be taken in doses, such as those described above, one to six times a day in a manner such that the total daily dose for
10 a 70 kg adult will generally be in the range of from 0.1 to 6000 mg, and more usually about 1 to 1500 mg.

In the treatment and/or prophylaxis of hyperglycaemic non-human mammals, especially dogs, the active ingredient may be administered by
15 mouth, usually once or twice a day and in an amount in the range of from about 0.025 mg/kg to 25 mg/kg, for example 0.1 mg/kg to 20 mg/kg. Similar dosage regimens are suitable for the treatment and/or prophylaxis of hyperlipidaemia in non-human mammals.

20 The dosages regimens for the treatment of hypertension, cardiovascular disease and eating disorders will generally be those mentioned above in relation to hyperglycaemia.


In a further aspect the present invention provides the use of a compound
25 of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperglycaemia.

30 The present invention also provides the use of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperlipidaemia, hypertension, cardiovascular disease or certain eating
35 disorders.

The following Procedures and Examples illustrate the invention but do not limit it in any way.

Procedure 12-(N-Benzoyl-N-methylamino)ethanol

5



10


Ethyl benzoate (16.0g, 15.3ml) was dissolved in 2-(N-methylamino)ethanol (200ml) and the mixture heated at reflux for 17.5 hours, cooled and diluted with water (1l). The mixture was extracted with dichloromethane (4x200ml), and the combined dichloromethane solutions washed with
15 brine (300ml), dried (MgSO₄) and evaporated. The title compound, an oil, was used without further purification.

¹H NMR δ (CDCl₃)

20 Some peaks in this spectrum are complicated by the presence of rotational isomers of the amide group.
3.05 (3H, s); 3.25 (1H, s, exchanges with D₂O); 3.50-4.00 (4H, broad); and 7.52 (5H, s).

25 Procedure 24-[2-(N-Benzoyl-N-methylamino)ethoxy]benzaldehyde.

30



35 Sodium hydride (60% dispersion in oil, 1.30g) was added portionwise to a solution of 2-(N-benzoyl-N-methylamino)ethanol (5.0g) in dry dimethylformamide (100ml) at room temperature under a nitrogen atmosphere. The mixture was stirred at room temperature for 1 hour

- 21 -

prior to the addition of 4-fluorobenzaldehyde (5.09g, 4.4ml), and the mixture then heated at 80°C for 15 hours. The solvent was evaporated and the residue dissolved in water (500ml) and extracted with ethyl acetate (3x500ml). The combined ethyl acetate layers were washed with water (2x300ml), brine (300ml), dried (MgSO₄) and evaporated to yield an oil. The oil was triturated with hexane, and the residue chromatographed on silica gel with 1.5% methanol in dichloromethane to afford the title compound as an oil.

10 ¹H NMR δ (CDCl₃)


Some peaks in this spectrum are complicated by the presence of rotational isomers of the amide group.

3.15 (3H, s); 3.85 (2H, apparent broad s); 4.30 (2H, apparent broad s); 7.00 (2H, br d); 7.47 (5H, s); 7.91 (2H, d); 9.97 (1H, s).

Procedure 3

2-(N-(5-Chloro-2-methoxybenzoyl)amino)ethanol


20



25 5-Chloro-2-methoxybenzoyl chloride (5.0g) was added to a vigorously stirred mixture of 2-aminoethanol (10.12g, 10ml) and sodium hydroxide solution (1M, 100ml). Stirring was continued for 2 hours at room temperature, then dilute hydrochloric acid (10% v/v, 100ml) was added and the mixture extracted with dichloromethane (3x200ml). The combined dichloromethane layers were dried (MgSO₄) and evaporated, and the resulting oil chromatographed on silica gel with 1% methanol in dichloromethane as solvent to afford the title compound as an oil.

35 ¹H NMR δ (CDCl₃)


3.30-3.80 (5H, complex; reduced to 4H on shaking with D₂O); 3.90 (3H, s); 6.83 (1H, d); 7.32 (1H, dd); 8.05 (1H, d); and 8.27 (1H, broad, exchanges with D₂O).

Procedure 44-[2-(N-(5-Chloro-2-methoxybenzoyl)amino)ethoxy]benzaldehyde

A mixture of 2-(N-(5-chloro-2-methoxybenzoyl)amino)ethanol (4.5g), potassium carbonate (5g) and 4-fluorobenzaldehyde (2.5g, 2.16ml) were heated at 100°C in dry dimethylsulphoxide (50ml) for 18 hours. The mixture was cooled, diluted with water and extracted with diethyl ether containing a little methanol. The organic layers were combined, dried (MgSO₄) and evaporated. The residual oil was chromatographed on silica gel with 2% methanol in dichloromethane as solvent to afford the title compound as an oil.

¹H NMR δ (CDCl₃)

3.70-4.05 (5H, complex); 4.22 (2H, t); 6.75-7.15 (3H, complex); 7.40 (1H, dd); 7.83 (2H, d); 8.17 (1H, d); 8.20 (1H, br, exchanges with D₂O); and 9.90 (1H, s).

Procedure 52-(N-Methyl-N-phenylacetyl)amino)ethanol.

The title compound, an oil, was prepared from ethyl phenylacetate (16.5g, 16ml) by a procedure similar to that described in Procedure 1.

- 23 -

 ^1H NMR δ (CDCl_3)

5 This spectrum is complicated by the presence of rotational isomers of the amide group.


2.90-3.20 (4H, complex; reduced to 3H on shaking with D_2O); 3.30-3.90 (6H, complex); and 7.37 (5H, s).

Procedure 6

10

4-[2-(N-Methyl-N-phenylacetyl-amino)ethoxy]benzaldehyde.

15



20 The title compound, an oil, was obtained when 2-(N-methyl-N-phenylacetyl-amino)ethanol (7.72g) was reacted with 4-fluorobenzaldehyde (7.52g, 6.5ml) by a method analogous to that described in Procedure 2.


 ^1H NMR δ (CDCl_3)

25 This spectrum is complicated by the presence of rotational isomers of the amide group.

3.05 and 3.15 (combined, 3H, singlets); 3.60-4.30 (6H, complex); 7.00 (2H, br d); 7.32 (5H, s); 7.88 (2H, d); and 9.95 (1H, s).

30 Procedure 74-[2-(N-Methyl-N-(2-pyridyl)acetyl-amino)ethoxy]benzaldehyde

35



- 24 -

Methyl 2-pyridylacetate (10.0g, 8.9ml) was dissolved in 2-(N-methyl-amino)ethanol (150ml) and the mixture heated at reflux for 84 hours, then cooled and concentrated under reduced pressure. The residue was dissolved in water (100ml) and continuously extracted overnight with ethyl acetate. The ethyl acetate solution was dried (MgSO_4) and evaporated to afford an oil which no longer displayed an ester signal ($\delta 3.70$) in the nmr spectrum. The oil was dissolved in dry dimethylformamide (150ml) at room temperature under a nitrogen atmosphere, and sodium hydride (60% dispersion in oil, 3.42g) was added. The mixture was stirred for 1 hour, then 4-fluorobenzaldehyde (10.6g, 9.2ml) was added and the mixture heated at 80°C for 22.5 hours, cooled, diluted with water (1l) and extracted with ethyl acetate (3x400ml). The combined ethyl acetate layers were washed with water (3x1l) and brine (1l), dried (MgSO_4) and evaporated. The resulting oil was triturated with hexane and the residue chromatographed on silica gel with 1.5% methanol in dichloromethane as solvent to afford the title compound as an oil.


^1H NMR δ (CDCl_3)

Some peaks in this spectrum are complicated by the presence of rotational isomers of the amide group.

3.03 and 3.25 (combined, 3H, singlets); 3.60-4.40 (6H, complex); 6.95 (2H, d); 7.00-7.75 (3H, complex); 7.85 (2H, d); 8.50 (1H, d); and 9.95 (1H, s).

Procedure 8

4-(2-Phthalimidoethoxy)benzaldehyde.



The title compound, mp 138°C , was prepared from N-(2-hydroxyethyl)-phthalimide (9.6g) and 4-fluorobenzaldehyde (6.2g, 5.3ml) by a procedure similar to that described in Procedure 2.

- 25 -


 ^1H NMR δ (CDCl_3)

4.05 (2H, t); 4.33 (2H, t); 7.10 (2H, d); 7.70-8.10 (6H, complex); and 9.82 (1H, s).

5

Procedure 94-[2-(2,3-Dihydro-1H-isoindol-1-on-2-yl)ethoxy]benzyl alcohol

10



15

4-(2-Phthalimidoethoxy)benzaldehyde (6.8g) was dissolved in glacial acetic acid (70ml) at 60°C. Powdered zinc (9.1g) was added, and the mixture heated at reflux and stirred vigorously for 18.25 hours before being filtered whilst hot, and allowed to cool to room temperature. The acetic acid was evaporated and the resulting gum dissolved in methanol (75ml). Sodium hydroxide solution (10% w/v; 75ml) was added, and the mixture stirred for 2 hours at room temperature, diluted with water (1l), acidified to pH4 with hydrochloric acid, and then continuously extracted with dichloromethane for 3 hours. The dichloromethane layer was evaporated and the residue chromatographed on silica gel using 1.5% methanol in dichloromethane to afford the title compound, mp 106-7°C.

20

25

 ^1H NMR δ (CDCl_3)


30

2.75 (1H, s, exchanges with D_2O); 3.93 (2H, t); 4.17 (2H, t); 4.60 (4H, apparent s); 6.85 (2H, d); and 7.10-7.90 (6H, complex).

35

Procedure 104-[2-(2,3-Dihydro-1H-isoindol-1-on-2-yl)ethoxy]benzaldehyde

5



- 10 A mixture of 4-[2-(2,3-dihydro-1H-isoindol-1-on-2-yl)-ethoxy]benzyl
alcohol (2.97g), manganese(IV) oxide (9.12g) and dichloromethane (180ml)
was stirred for 3 hours at room temperature. The mixture was filtered
through a Soxhlet thimble and the residue extracted with refluxing
dichloromethane for 3 hours. The solvent was then evaporated to afford
15 the title compound, mp 134-5°C.


 ^1H NMR δ (CDCl_3)

- 4.03 (2H, t); 4.32 (2H, t); 4.60 (2H, s); 7.10 (2H, d); 7.55 (3H, complex);
20 7.85 (3H, complex); and 9.95
(1H, s).

Procedure 11

- 25 3-Phthalimidopropanol methanesulphonyl ester

30



- Methanesulphonyl chloride (5.72g; 4.25ml) was added dropwise to a
stirred, ice cooled mixture of N-(3-hydroxypropyl)phthalimide (10.26g) and
triethylamine (6.09g, 8.4ml) in dichloromethane (250ml). The mixture
35 was stirred at 0°C for 1.5 hours, then washed with water (3x300ml),
saturated sodium bicarbonate solution (300ml), and brine (300ml), dried
(MgSO_4) and evaporated. The title compound, mp 133-5°C, was used
without further purification.


- 27 -

 ^1H NMR δ (CDCl_3)

2.15 (2H, complex); 3.05 (3H, s); 3.82 (2H, t); 4.25 (2H, t); and 7.50-7.90
5 (4H, complex).

Procedure 124-(3-Phthalimidopropoxy)benzaldehyde

10



15 Sodium hydride (60% dispersion in oil, 2.01g) was added to a stirred
solution of 4-hydroxybenzaldehyde (5.25g) in dry dimethylformamide
(100ml) under a nitrogen atmosphere at room temperature, and the
mixture stirred for 30 minutes. A solution of 3-phthalimidopropanol
methanesulphonyl ester (12.2g) in dry dimethylformamide (200ml) was
20 added, and stirring continued at 80°C for 14.5 hours. After cooling the
mixture was diluted with water (2l) and extracted with ethyl acetate
(4x400ml). The combined organic layers were washed with water (4x1l)
and brine (1l), dried (MgSO_4) and evaporated. Chromatography on silica
gel with dichloromethane as solvent afforded the title compound, mp 122-
25 5°C.


 ^1H NMR δ (CDCl_3)

2.27 (2H, complex); 3.95 (2H, t); 4.13 (2H, t); 6.95 (2H, d); 7.60-8.20 (6H,
30 complex); and 9.95 (1H, s).

35

Procedure 134-[3-(2,3-Dihydro-1H-isoindol-1-on-2-yl)propoxy]benzyl alcohol

5



10 The title compound, mp 121-4°C, was prepared from 4-(3-phthalimido propoxy)benzaldehyde (9.27g) by a method analogous to that described in Procedure 9.


¹H NMR δ (CDCl₃)

15

2.10 (2H, complex); 2.63 (1H, s, exchanges with D₂O); 3.70 (2H, t); 3.95 (2H, t); 4.35 (2H, s); 4.55 (2H, s); 6.77 (2H, d); and 7.10-7.90 (6H, complex).

20 Procedure 144-[3-(2,3-Dihydro-1H-isoindol-1-on-2-yl)propoxy]benzaldehyde

25



The title compound, mp 113-5°C, was prepared from 4-[3-(2,3-dihydro-1H-isoindol-1-on-2-yl)propoxy]benzyl alcohol (4.41g) by a method analogous so
30 that described in Procedure 10.


¹H NMR δ (CDCl₃)

2.17 (2H, complex); 3.80 (2H, t); 4.10 (2H, t); 4.40 (2H, s); 6.95 (2H,s); 7.50
35 (3H, complex); 7.75 (3H, complex); and 9.92 (1H, s).

- 29 -

Procedure 154-(2-Hydroxyethoxy)benzaldehyde methanesulphonyl ester

5



10 4-(2-Hydroxyethoxy)benzaldehyde (14.1g) was reacted with methanesulphonyl chloride (10.7g; 7.23ml) in a manner analogous to that described in Procedure 11. The crude product was chromatographed on silica gel with 1.5% methanol in dichloromethane as solvent to afford the title compound, mp 66-7°C.

15


¹H NMR δ (CDCl₃)

3.10 (3H, s); 4.37 (2H, t); 4.60 (2H, t); 7.07 (2H, d); 7.90 (2H, d); and 9.95 (1H, s).

20

Procedure 164-[2-(3,4-Dihydro-2H-isoquinolin-1-on-2-yl)ethoxy]benzaldehyde

25



30 3,4-Dihydro-2H-isoquinolin-1-one (5.14g) was dissolved in dry tetrahydrofuran (100ml) at 0°C under a nitrogen atmosphere and treated with sodium hydride (60% dispersion, 1.54g). The mixture was allowed to warm to room temperature over 30 minutes prior to the addition of a solution of 4-(2-hydroxyethoxy)benzaldehydemethanesulphonyl ester (8.54g) in tetrahydrofuran (150ml). After stirring the mixture at room temperature for 15 minutes, it was heated at reflux for 23 hours, cooled and evaporated. The residue was suspended in water (1l), acidified with dilute hydrochloric acid, and then extracted with ethyl acetate (3x400ml).
35 The combined organic layers were washed with water (1l), brine (1l), dried

- 30 -

(MgSO₄) and evaporated. The residue was chromatographed on silica gel with 1% methanol in dichloromethane as solvent to afford the title compound, mp 131-4°C.


5 ¹H NMR δ (CDCl₃)

2.95 (2H, apparent t); 3.60-4.10 (4H, complex); 4.30 (2H, t); 6.85-7.55 (5H, complex); 7.80 (2H, d); 8.00 (1H, complex); and 9.83 (1H, s).

10 Procedure 17

4-(N-Methylaminocarbonylmethoxy)benzaldehyde

15



4-(Methoxycarbonylmethoxy)benzaldehyde (19.5g) was dissolved in a solution of methylamine in ethanol (8M; 300ml). The flask was sealed and kept at room temperature for 18.5 hours before being opened and the contents evaporated. The residue was dissolved in ethanol (100ml) and dilute hydrochloric acid (200ml) and stirred at room temperature for 3 hours before being continuously extracted with dichloromethane for 6 hours. Evaporation of the dried (MgSO₄) dichloromethane solution afforded the title compound, mp 122-5°, which was used without further purification.

25 ¹H NMR δ (CDCl₃)


30 2.95 (3H, apparent d); 4.65 (2H, s); 6.83 (1H, broad s); 7.13 (2H, d); 7.95 (2H, d); and 10.05 (1H, s).

35

- 31 -

Procedure 184-[2-(Methylamino)ethoxy]benzyl alcohol

5



- 10 A solution of 4-(N-methylaminocarbonylmethoxy)benzaldehyde (9.65g) in dry tetrahydrofuran (300 ml) was added slowly to a stirred, ice-cooled suspension of lithium aluminium hydride (9.5g) in dry tetrahydrofuran (100ml) under a nitrogen atmosphere. The resulting mixture was warmed at reflux for 12 hours, then cooled in ice during the addition of water
- 15 (9.5ml), 10% aqueous sodium hydroxide (9.5ml) and water (28.5ml). The mixture was heated at reflux for 10 minutes, then filtered through a Soxhlet thimble and the residue Soxhlet extracted with tetrahydrofuran. Evaporation of the combined tetrahydrofuran layers afforded the title compound as an oil which was used without further purification.

20


 ^1H NMR δ (CDCl_3)

2.40 (3H, s); 2.95 (2H, t); 3.21 (2H, br s, exchanges with D_2O); 4.05 (2H, t); 4.65 (2H, s); 6.90 (2H, d); and 7.35 (2H, d).

25

Procedure 194-[2-[N-Methyl-N-(3-phenylpropanoyl)amino]ethoxy]benzyl alcohol

30



- 35 Trimethylsilyl chloride (2.17g, 2.54ml) was added to an ice-cooled solution of 4-[2-(methylamino)ethoxy]benzyl alcohol (3.78g), triethylamine (4.50g, 6.2ml) and 4-dimethylaminopyridine (0.4g) in dichloromethane (200ml). The mixture was stirred at 0°C for 1.5 hours prior to the addition of 3-

- 32 -

phenylpropanoyl chloride (3.37g, 2.97ml), and the mixture then stirred at room temperature for 16 hours. Hydrofluoric acid (48%, 1ml) was added and the mixture stirred at room temperature for 15 minutes, then diluted with dilute hydrochloric acid (50ml) and stirred for a further 3.5 hours.

- 5 Water (200ml) was added and the layers separated. The organic layer was washed with saturated sodium bicarbonate solution (400ml), water (2x400ml), brine (400ml), dried (MgSO_4) and evaporated. The residue was chromatographed on silica gel with 1.5% methanol in dichloromethane to afford the title compound as an oil.

10

^1H NMR δ (CDCl_3)


This spectrum is complicated by the presence of rotational isomers of the amide group.

- 15 2.40-3.00 (5H, complex; reduced to 4H on shaking with D_2O); 3.00 and 3.10 (combined, 3H singlets); 3.60 and 3.70 (combined, 2H, rotameric triplets); 4.62 (2H, s); and 6.70-7.40 (9H, complex).

Procedure 20

20

4-[2-[N-Methyl-N-(3-phenylpropanoyl)amino]ethoxy]benzaldehyde



- 30 4-[2-[N-Methyl-N-(3-phenylpropanoyl)amino]ethoxy]benzyl alcohol (3.40g) was oxidised with manganese (IV) oxide (9.4g) in a manner analogous to that described in Procedure 10, to afford the title compound as a gum.

^1H NMR δ (CDCl_3)

This spectrum is complicated by the presence of rotational isomers of the amide group.


- 35 2.50-3.20 (7H, complex); 3.75 (2H, broad apparent triplet); 3.95-4.30 (2H, complex); 6.93 (2H, broad d); 7.17 (5H, s); 7.77 (2H, d); and 9.85 (1H, s).

- 33 -

Example 15-(4-[2-(N-Benzoyl-N-methylamino)ethoxy]benzylidene)-
2,4-thiazolidinedione.

5

10




A mixture of 4-[2-(N-benzoyl-N-methylamino)ethoxy]benzaldehyde (3.94g), 2,4-thiazolidinedione (1.79g), benzoic acid (0.2g) and piperidine (0.2ml) were heated at reflux in toluene (250ml) in a Dean and Stark apparatus. After 5 hours at reflux the mixture was allowed to cool and crystallise overnight. The title compound, mp 178-180°C, was filtered off, washed with cold toluene and dried under vacuum.

20 ¹H NMR δ (DMSO-d₆; 80°C)

This spectrum is complicated by the presence of rotational isomers of the amide group. These coalesce at 80°C.
3.01 (3H, s); 3.75 (2H, t); 4.26 (2H, t); 7.07 (2H, d); 7.30-7.60 (7H, complex); 7.71 (1H, s); and 12.25 (1H, br s, exchanges with D₂O).

Example 230 5-(4-[2-(N-Benzoyl-N-methylamino)ethoxy]benzyl)-
2,4-thiazolidinedione.

35



- 34 -

5-(4-[2-(N-Benzoyl-N-methylamino)ethoxy]benzylidene)-2,4-thiazolidine-dione (4.01g) was dissolved in dioxan (400ml) and hydrogenated at room temperature and pressure in the presence of 10% palladium-charcoal (4g) for 3.5 hours. A further portion of catalyst (4g) was added, and the reaction continued for a total of 52 hours. The reaction mixture was filtered through diatomaceous earth, and the solvent evaporated. The resulting gum was recrystallised from dichloromethane-diethyl ether to afford the title compound, mp 139-142°C.


10 ^1H NMR δ (CDCl_3)

This spectrum is complicated by the presence of rotational isomers of the amide group.

3.00-3.20 (4H, complex); 3.44 (1H, dd); 3.68 and 3.92 (combined, 2H, apparent broad singlets); 3.99 and 4.27 (Combined, 2H, apparent broad singlets); 4.45 (1H, dd); 6.70-7.50 (9H, complex); and 8.78 (1H, br s, exchanges with D_2O).

20 Example 3


5-(4-[2-(N-(5-Chloro-2-methoxybenzoyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione.



30 The title compound, mp 213-4°C, was prepared from 4-[2-(N-(5-chloro-2-methoxybenzoyl)amino)ethoxy]benzaldehyde (1.7g) by a method similar to that described in Example 1.

35 ^1H NMR δ ($\text{DMSO}-d_6$)


3.66 (2H, complex); 3.86 (3H, s); 4.19 (2H, t); 7.15 (3H, complex); 7.45-7.80 (5H, complex), 8.47 (1H, br, exchanges with D_2O); and 12.50 (1H, br, exchanges with D_2O).

Example 45-(4-[2-(N-(5-Chloro-2-methoxybenzoyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione.

5-(4-[2-(N-(5-Chloro-2-methoxybenzoyl)amino)ethoxy]-benzylidene)-2,4-thiazolidinedione (1.7g) was dissolved in dioxan (80ml) and hydrogenated for a total of 22 hours in a manner similar to that described in Example 2. The title compound was obtained as a foam, mp 66-67°C.

¹H NMR δ (DMSO-d₆)

3.06 (1H, dd); 3.31 (1H, dd); 3.65 (2H, complex); 3.87 (3H, s); 4.09 (2H, t); 4.87 (1H, dd); 6.92 (2H, d); 7.17 (3H, apparent d); 7.52 (1H, dd); 7.71 (1H, d); 8.45 (1H, t, exchanges with D₂O); and 12.03 (1H, br s, exchanges with D₂O).

Example 55-(4-[2-(N-Methyl-N-phenylacetyl)amino)ethoxy]-benzylidene)-2,4-thiazolidinedione.

The title compound, mp 145-8°C, was prepared from 4-[2-(N-methyl-phenylacetyl)amino)ethoxy]benzaldehyde (5.6g) by a procedure analogous

- 36 -

to that described in Example 1.

^1H NMR δ ($\text{CDCl}_3/\text{DMSO}-d_6$; 1:1)

5 This spectrum is complicated by the presence of rotational isomers of the amide group.


3.02 and 3.15 (combined 3H, singlets); 3.65-3.90 (4H, complex); 4.15 (2H, complex); 7.00 (2H, br d); 7.10-7.60 (7H, complex); 7.77 (1H,s); and 12.20 (1H, br s, exchanges with D_2O).

10

Example 6

5-(4-[2-(N-Methyl-N-phenylacetyl-amino)ethoxy]benzyl)-
2,4-thiazolidinedione.

15



20

25 5-(4-[2-(N-Methyl-N-phenylacetyl-amino)ethoxy]benzylidene)-
2,4-thiazolidinedione (5.75g) was dissolved in dioxan (450ml) and
hydrogenated for a total of 48 hours in a manner analogous to that
described in Example 2. The title compound, a foam mp 45-9°C, was
obtained following chromatography of the reaction mixture on silica gel
with 1.5% methanol in dichloromethane as solvent.

30 ^1H NMR δ ($\text{DMSO}-d_6$; 120°C)


This spectrum is complicated by the presence of rotational isomers of the amide group. These coalesce at 120°C.

2.99 (3H, s); 3.06 (1H, dd); 3.32 (1H, dd); 3.67 (2H, t); 3.70 (2H, s); 4.09
35 (2H, t); 4.75 (1H, dd); 6.84 (2H, d); 7.05-7.35 (7H complex); and 12.00 (1H,
s exchanges with D_2O).

- 37 -

Example 75-(4-[2-(N-Methyl-N-(2-pyridyl)acetyl-amino)ethoxy]benzylidene)-2,4-thiazolidinedione

5



10

The title compound, mp 232-234°C was prepared from 4-[2-(N-methyl-N-(2-pyridyl)acetyl-amino)ethoxy]benzaldehyde (5.59g) by a method similar to that described in Example 1.

15 ¹H NMR δ (CF₃CO₂D)

This spectrum is complicated by the presence of rotational isomers of the amide group.


20 3.20 and 3.42 (combined, 3H, singlets); 3.80-4.45 (4H, complex); 4.47 and 4.70 (combined, 2H, singlets); 7.05 (2H, d); 7.55 (2H, d); 7.90-8.15 (3H, complex); 8.60 (1H, broad apparent triplet); and 8.85 (1H, d). The imide proton exchanges with the solvent.

Example 8

25

5-(4-[2-(N-Methyl-N-(2-pyridyl)acetyl-amino)ethoxy]-benzyl)-2,4-thiazolidinedione

30



35 5-(4-[2-(N-Methyl-N-(2-pyridyl)acetyl-amino)ethoxy]benzylidene)-2,4-thiazolidinedione (5.25g) was suspended in dioxan (400ml) and hydrogenated over 10% palladium-charcoal (11.5g total) for a total of 45 hours in a manner analogous to that described in Example 2. The

- 38 -

reaction mixture was filtered and evaporated and the residue triturated with a boiling mixture of dichloromethane-hexane (3:1; 100ml) to afford the title compound as a solid, mp 147 - 160°C. ¹H NMR analysis showed this material to contain 10% by weight of unreduced benzylidene precursor.

¹H NMR δ (DMSO-d₆; 140°C)


This spectrum is complicated by the presence of rotational isomers of the amide group. These coalesce at 140°C.

3.00-3.15 (4H, complex); 3.29 (1H, dd); 3.73 (2H, t); 3.86 (2H, s); 4.11 (2H, t); 4.73 (1H, dd); 6.85 (2H, d); 7.00-7.70 (5H, complex); 8.42 (1H, dd); and 11.50 (1H, br s, exchanges with D₂O).

In addition, this spectrum shows peaks corresponding to 0.1 equivalent of the benzylidene precursor (Example 7).

Example 9

5-(4-[2-(2,3-Dihydro-1H-isoindol-1-on-2-yl)ethoxy]benzylidene)-2,4-thiazolidinedione



The title compound, mp 229-230°C, was prepared from 4-[2-(2,3-dihydro-1H-isoindol-1-on-2-yl)ethoxy]-benzaldehyde (3.8g) by a procedure analogous to that described in Example 1.


¹H NMR δ (CDCl₃/DMSO-d₆; 1:1)

4.00 (2H, t); 4.30 (2H, t); 4.62 (2H, s); 7.00-7.80 (9H, complex); and 12.40 (1H, br s, exchanges with D₂O).

- 39 -

Example 105-(4-[2-(2,3-Dihydro-1H-isoindol-1-on-2-yl)ethoxy]benzyl)-2,4-thiazolidinedione

5



10

5-(4-[2-(2,3-Dihydro-1H-isoindol-1-on-2-yl)ethoxy]benzylidene)-2,4-thiazolidinedione (3g) was suspended in dioxan (250ml) and hydrogenated over 10% palladium-charcoal (6g total) for 51 hours by a method analogous to that described in Example 2. The mixture was filtered and the solvent evaporated to afford a solid. Recrystallisation from dichloromethane-hexane gave the title compound, mp 153-5°C.


¹H NMR δ (CDCl₃)

20

3.09 (1H, dd); 3.42 (1H, dd); 4.01 (2H, t); 4.20 (2H, t); 4.47 (1H, dd); 4.62 (2H, s); 6.84 (2H, d); 7.14 (2H, d); 7.40-7.60 (3H, complex); 7.85 (1H, d); and 8.91 (1H, br s, exchanges with D₂O).

25 Example 115-[4-[3-(2,3-Dihydro-1H-isoindol-1-on-2-yl)propoxy]benzylidene]-2,4-thiazolidinedione.

30



35 The title compound, mp 260-263°C, was prepared from 4-[3-(2,3-dihydro-1H-isoindol-1-on-2-yl)propoxy]benzaldehyde (4.22g) by a method analogous to that described in Example 1.


^1H NMR δ (CDCl_3)

2.09 (2H, complex); 3.70 (2H, t); 4.10 (2H, t); 4.52 (2H, s); 7.07 (2H, d); 7.45-7.80 (7H, complex); and 12.49 (1H, br s, exchanges with D_2O).

5

Example 125-[4-[3-(2,3-Dihydro-1H-isoindol-1-on-2-yl)propoxy]benzyl]-2,4-thiazolidinedione

10



15 The title compound, mp $135-8^\circ\text{C}$, was prepared from 4-[3-(2,3-dihydro-1H-isoindol-1-on-2-yl)propoxy]benzylidene]-2,4-thiazolidinedione (4.00g) by a method analogous to that described in Example 10.


 ^1H NMR δ ($\text{DMSO}-d_6$)

20

2.05 (2H, complex); 3.02 (1H, dd); 3.27 (1H, dd); 3.68 (2H, t); 3.99 (2H, t); 4.51 (2H, s); 4.86 (1H, dd); 6.85 (2H, d); 7.12 (2H, d); 7.40-7.75 (4H, complex); and 12.02 (1H, br s).

25 Example 135-[4-[2-(3,4-Dihydro-2H-isoquinolin-1-on-2-yl)ethoxy]benzylidene]-2,4-thiazolidinedione

30



35 The title compound, mp $180-183^\circ\text{C}$, was prepared from 4-[2-(3,4-dihydro-2H-isoquinolin-1-on-2-yl)ethoxy]benzaldehyde (4.21g) by a method analogous to that described in Example 1.

- 41 -


 ^1H NMR δ ($\text{CDCl}_3/\text{DMSO}-d_6$; 1:1)

2.89 (2H, apparent t); 3.40 - 4.00 (4H, complex); 4.20 (2H, t); 6.85-8.00 (9H, complex); and 12.35 (1H, broad singlet, exchanges with D_2O).

5

Example 145-[4-[2-(3,4-Dihydro-2H-isoquinolin-1-one-2-yl)ethoxy]benzyl]-2,4-thiazolidinedione

10



15 The title compound, mp $136-9^\circ\text{C}$, was prepared from 5-[4-[2-(3,4-dihydro-2H-isoquinolin-1-one-2-yl)ethoxy]benzylidene]-2,4-thiazolidinedione (4.4g) by a method analogous to that described for Example 2.


 ^1H NMR δ ($\text{DMSO}-d_6$)

20

2.95 (2H, t); 3.03 (1H, dd); 3.27 (1H, dd); 3.67 (2H, t); 3.83 (2H, t); 4.16 (2H, t); 4.84 (1H, dd); 6.91 (2H, d); 7.14 (2H, d); 7.25-7.55 (3H, complex); 7.87 (1H, d); and 12.00 (1H, broad s; exchanges with D_2O).

25 Example 155-[4-[2-[N-Methyl-N-(3-phenylpropanoyl)amino]ethoxy]benzylidene]-2,4-thiazolidinedione

30




35 The title compound, mp $172-5^\circ\text{C}$, was prepared from 4-[2-[N-methyl-N-(3-phenylpropanoyl)amino]ethoxy]benzaldehyde (3.17g) by a method analogous to that described in Example 1.

- 42 -

 ^1H NMR δ (CDCl_3)

This spectrum is complicated by the presence of rotational isomers of the amide group.

- 5 2.50-3.00 (4H, complex); 2.95 and 3.10 (combined, 3H, singles); 3.75 (2H, apparent broad t); 4.20 (2H, complex); 6.85-7.60 (9H, complex); 7.75 (1H, s); and 11.50 (1H, broad s).

Example 165-[4-[2-[N-Methyl-N-(3-phenylpropanoyl)amino]ethoxy]benzyl]-2,4-thiazolidinedione.

The title compound, a foam mp 50°C , was prepared from 5-[4-[2-[N-methyl-N-(3-phenylpropanoyl)amino]ethoxy]benzylidene]-2,4-thiazolidinedione (3.50g) in a manner analogous to that described for

20 Example 2.

 ^1H NMR δ ($\text{DMSO}-d_6/\text{D}_2\text{O}$); 120°C

- 25 This spectrum is complicated by the presence of rotational isomers of the amide group. These coalesce at 120°C .
2.63 (2H, t); 2.86 (2H, t); 2.94 (3H, s); 3.06 (1H, dd); 3.30 (1H, dd); 3.64 (2H, t); 4.07 (2H, t); 4.73 (1H, dd); 6.85 (2H, d); 7.05-7.30 (7H, complex).

- 43 -

DEMONSTRATION OF EFFICACY OF COMPOUNDSObese Mice, Oral Glucose Tolerance Test.

- 5 C57bl/6 obese (ob/ob) mice were fed on powdered oxoid diet. After at least one week, the mice continued on a powdered oxoid diet or were fed powdered oxoid diet containing the test compound. After 8 days on the supplemented diet all of the mice were fasted for 5 hours prior to receiving an oral load of glucose (3 g/kg). Blood samples for glucose analysis were
- 10 taken 0, 45, 90 and 135 minutes after glucose administration and the results appear below as the percentage reduction in area under the blood glucose curve where test compound treated groups are compared with the control groups. 7 mice were used for each treatment.

<u>EXAMPLE NO:</u>	<u>LEVEL IN</u>	<u>%REDUCTION IN AREA</u>
	<u>DIET</u> <u>(mmol kg⁻¹ of</u>	<u>UNDER BLOOD GLUCOSE</u> <u>CURVE</u>
	<u>DIET)</u>	
2	300	19
4	1000	27
6	300	52
8	300	32
10	300	44
12	1000	32
14	300	29
16	300	17

15


Toxicology

No toxicological effects were indicated for any of the compounds of the invention in any of the abovementioned tests.

20

Claims

1. A compound of formula (I):



10

or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A^1 represents an alkyl group, a substituted or unsubstituted aryl group, an aralkyl group wherein the alkylene or the aryl moiety may be substituted or unsubstituted or a substituted or unsubstituted aromatic heterocyclyl group;

15

A^2 represents a benzene ring having in total up to three optional substituents;

R^1 represents a hydrogen atom, an alkyl group, an aralkyl group wherein the alkyl or the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

20

or A^1 together with R^1 represents substituted or unsubstituted C_{3-4} polymethylene group, optional substituents for the polymethylene group being selected from alkyl or aryl or adjacent substituents together with the methylene carbon atoms to which they are attached form a substituted or unsubstituted phenylene group;

25

R^2 and R^3 each represent hydrogen, or R^2 and R^3 together represent a bond;

X represents O or S; and

30

n represents an integer in the range of from 2 to 6.

2. A compound according to claim 1, wherein A^1 together with R^1 represents substituted or unsubstituted C_{3-4} polymethylene group, optional substituents for the polymethylene group being selected from alkyl or aryl or adjacent substituents together with the methylene carbon atoms to which they are attached form a substituted or unsubstituted phenylene group;

35


-45-

3. A compound according to claim 1 or claim 2, wherein the moiety $A^1\text{-CO-NR}^1$ represents a 2,3-dihydro-1H-isoindol-1-on-2-yl group or a 3,4-dihydro-2H-isoquinolin-on-2-yl group wherein the phenylene moiety may be substituted or unsubstituted.

5

4. A compound according to any one of claims 1 to 3, wherein the moiety $A^1\text{-CO-NR}^1$ represents a 2,3-dihydro-1H-isoindol-1-on-2-yl moiety.

10 5. A compound according to any one of claims 1 to 4, wherein A^2 represents a moiety of formula (a):



15

(a)

wherein R^4 and R^5 each independently represent hydrogen, halogen, substituted or unsubstituted alkyl or alkoxy.

20 6. A compound according to any one of claims 1 to 5, wherein R^1 represents a methyl group.

25 7. A compound according to any one of claims 1 to 6, wherein R^2 and R^3 each represent hydrogen.

25

8. A compound according to claim 1, selected from the list consisting of:

30 5-(4-[2-(N-benzoyl-N-methylamino)ethoxy]benzylidene)-2,4-thiazolidinedione;

5-(4-[2-(N-benzoyl-N-methylamino)ethoxy]benzyl)-2,4-thiazolidinedione;

35 5-(4-[2-(N-(5-chloro-2-methoxybenzoyl)amino)ethoxy]-benzylidene)-2,4-thiazolidinedione;

- 46 -


- 5-(4-[2-(N-(5-chloro-2-methoxybenzoyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 5 5-(4-[2-(N-methyl-N-phenylacetyl-amino)ethoxy]-benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-phenylacetyl-amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 10 5-(4-[2-(N-methyl-N-(2-pyridyl)acetyl-amino)ethoxy]-benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-(2-pyridyl)acetyl-amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 15 5-(4-[2-(N-methyl-N-(2-pyridyl)acetyl-amino)ethoxy]-benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(2,3-dihydro-1H-isoindol-1-on-2-yl)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 20 5-(4-[2-(2,3-dihydro-1H-isoindol-1-on-2-yl)ethoxy]benzyl)-2,4-thiazolidinedione;
- 25 5-[4-[3-(2,3-dihydro-1H-isoindol-1-on-2-yl)propoxy]benzyl]-2,4-thiazolidinedione;
- 5-[4-[3-(2,3-dihydro-1H-isoindol-1-on-2-yl)propoxy]benzylidene]-2,4-thiazolidinedione;
- 30 5-[4-[2-(3,4-dihydro-2H-isoquinolin-1-on-2-yl)ethoxy]benzylidene]-2,4-thiazolidinedione;
- 5-[4-[2-(3,4-dihydro-2H-isoquinolin-1-one-2-yl)ethoxy]benzyl]-2,4-thiazolidinedione;
- 35 5-[4-[2-[N-methyl-N-(3-phenylpropanoyl)amino]ethoxy]benzylidene]-2,4-thiazolidinedione; and

-47-

5-[4-[2-[N-methyl-N-(3-phenylpropanoyl)amino]ethoxy]benzyl]-2,4-thiazolidinedione; or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof..


9. A process for the preparation of a compound of formula (I), or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, which process comprises:

a) reacting a compound of formula (II):



(II)


wherein R^2 , R^3 and A^2 are as defined in relation to formula (I), and R^a is a moiety convertible to a moiety of formula (b):



(b)

wherein A^1 , R^1 , X and n are as defined in relation to formula (I), with an appropriate reagent capable of converting R^a to the said moiety (b); or

b) reacting a compound of formula (XI):



(XI)

-48-

wherein R¹, A¹, A², X and n are as defined in relation to formula (I) with 2,4-thiazolidinedione; and thereafter if required carrying out one or more of the following optional steps:

- 5 (i) converting a compound of formula (I) into a further compound of formula (I);
- (ii) preparing a pharmaceutically acceptable salt of a compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.
- 10 10. A pharmaceutical composition comprising a compound of formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.
- 15 11. A compound of formula (I), or tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance.
- 20 12. A compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of hyperglycaemia.
- 25 13. A compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment and/or prophylaxis of hyperlipidaemia, hypertension, cardiovascular disease and certain eating disorders.
- 30 14. A method for the treatment and/or prophylaxis of hyperglycaemia in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a
- 35 pharmaceutically acceptable solvate thereof to a hyperglycaemic human or non-human mammal in need thereof.

- 49 -

15. A method for the treatment of hyperlipidaemia, hypertension, cardiovascular disease and certain eating disorders in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.
16. The use of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperglycaemia.
17. The use of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperlipidaemia, hypertension, cardiovascular disease or certain eating disorders.

INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 91/01833

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC5: C 07 D 417/12, 277/34, A 61 K 31/425		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC5	C 07 D; A 61 K	
Documentation Searched other than Minimum Documentation to the extent that such Documents are Included in Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P,X	EP, A1, 0415605 (BEECHAM GROUP P.L.C.) 6 March 1991, see the claims --	1-13, 16, 17
X	EP, A1, 0306228 (BEECHAM GROUP PLC) 8 March 1989, see the claims; page 36, lines 1-23 --	1-13, 16, 17
X	EP, A1, 0295828 (BEECHAM GROUP PLC) 21 December 1988, see the claims; page 9, 10 --	1-13, 16, 17
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
8th January 1992	24 JAN 1992	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	MISS T. TAZELAAR	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
P,X	EP, A1, 0419035 (BEECHAM GROUP P.L.C.) 27 March 1991, see the claims --	1-13,16, 17
X	Chem. Pharm. Bull., vol. 30, No. 10, 1982, T. Sohda et al.: "Studies on antidiabetic agents. II. Synthesis of 5-(4-(1-methylcyclohexylmethoxy)- benzyl)thiazolidine-2,4-dione (ADD-3878) and its derivatives ", see page 3580 - page 3600 see page 3589, lines 10-12; page 3587, Table V, compounds nos 76-80,82 --	1-13,16, 17
A	EP, A2, 0332331 (PFIZER INC.) 13 September 1989, see the claims -- -----	1-13,16, 17

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 14, 15 because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the the claims. It is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/GB 91/01833**

SA 52312

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 31/10/91. The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0415605	06/03/91	AU-D- 6128590 JP-A- 3090071	28/02/91 16/04/91
EP-A1- 0306228	08/03/89	AU-D- 2173888 JP-A- 1131169 US-A- 5002953	09/03/89 24/05/89 26/03/91
EP-A1- 0295828	21/12/88	JP-A- 1013076 US-A- 4918091	17/01/89 17/04/90
EP-A1- 0419035	27/03/91	JP-A- 3090078	16/04/91
EP-A2- 0332331	13/09/89	WO-A- 89/08650	21/09/89

For more details about this annex : see Official Journal of the European patent Office, No. 12/82

THIS PAGE BLANK (USPTO)